Strategies and outcome for patients with high-risk acute promyelocytic leukemia (APL).
| Author/Study . | N . | Treatment . | CR, % . | ED, % . | EFS, % . | OS, % . |
|---|---|---|---|---|---|---|
| *Relapse-free survival | ||||||
| Abbreviations: CR, complete response; ED, early death; EFS, event-free survival; OS, overall survival; ara-C, cytosine arabinoside; ATO, arsenic trioxide; ATRA, all-trans retinoic acid; GO, gemtuzumab ozogamicin; ida, idarubicin | ||||||
| Ades/PETHEMA LPA99 trial50 | 104 | Increased anthracycline | 83.6 | 16.4 | 67.3 at 3 y | 80.8 at 3 y |
| Ades/European APL Group APL2000 trial50 | 99 | High-dose ara-C in consolidation | 95.1 | 4.9 | 82.2 at 3 y | 91.5 at 3 y |
| Powell/North American Intergroup C971051 | 112 | ATO in consolidation | 75 | 16 | 65 at 3 y | 86 at 3 y |
| Lengfelder/German AML Coop Group45 | 37 | High-dose ara-C in induction | 83.8 | 16.2 | 63 at 6 y | 73 at 6 y |
| Estey/MD Anderson Cancer Center37 | 19 | ATRA + ATO + GO or ida | 79 | 21 | 90 at 2 y* | 90 at 2 y |
| Author/Study . | N . | Treatment . | CR, % . | ED, % . | EFS, % . | OS, % . |
|---|---|---|---|---|---|---|
| *Relapse-free survival | ||||||
| Abbreviations: CR, complete response; ED, early death; EFS, event-free survival; OS, overall survival; ara-C, cytosine arabinoside; ATO, arsenic trioxide; ATRA, all-trans retinoic acid; GO, gemtuzumab ozogamicin; ida, idarubicin | ||||||
| Ades/PETHEMA LPA99 trial50 | 104 | Increased anthracycline | 83.6 | 16.4 | 67.3 at 3 y | 80.8 at 3 y |
| Ades/European APL Group APL2000 trial50 | 99 | High-dose ara-C in consolidation | 95.1 | 4.9 | 82.2 at 3 y | 91.5 at 3 y |
| Powell/North American Intergroup C971051 | 112 | ATO in consolidation | 75 | 16 | 65 at 3 y | 86 at 3 y |
| Lengfelder/German AML Coop Group45 | 37 | High-dose ara-C in induction | 83.8 | 16.2 | 63 at 6 y | 73 at 6 y |
| Estey/MD Anderson Cancer Center37 | 19 | ATRA + ATO + GO or ida | 79 | 21 | 90 at 2 y* | 90 at 2 y |